858 Therapeutics key facts
- Operator of a biotechnology company intended to discover innovative therapeutics for the treatment of cancers that are resistant to current therapies.
- 858 Therapeutics’s last known valuation is $140.0M.
- It has raised $110.0M across 3 recorded rounds; the latest was Early Stage VC ($25.2M) in Jun 2024.
- Notable investors include Insight Partners (New York), New Enterprise Associates, Alexandria Venture Investments, Mirae Asset Capital, Cormorant Asset Management — 8 tracked in total.
- 858 Therapeutics has filed 3 Form Ds with the SEC since 2020, most recently Jul 2024 ($25.2M sold to 12 investors).
- Status: Privately Held (backing).
- ·Watch 858 Therapeutics: the Monday email on marks, rounds and moves
858 Therapeutics funding rounds
3 rounds858 Therapeutics valuation
858 Therapeutics's last known valuation is $140 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
How much has 858 Therapeutics raised?
858 Therapeutics has raised $110 million across 3 recorded rounds since 2020. The largest was a $25.2 million early-stage round in Jun 2024.
858 Therapeutics has filed 3 Form Ds with the SEC since 2020, most recently in Jul 2024 ($25.2 million sold to 12 investors).
858 Therapeutics investors
8 investors are on record for 858 Therapeutics, including Insight Partners (New York), New Enterprise Associates, Alexandria Venture Investments and Mirae Asset Capital. By type, the record holds 4 venture capital firms, 1 hedge fund and 1 asset manager. The early-stage round in Jun 2024 drew 12 investors.
About 858 Therapeutics
Operator of a biotechnology company intended to discover innovative therapeutics for the treatment of cancers that are resistant to current therapies. The company's platform offers to assess the impact of ribonucleic acid modifying proteins on disease biology and generating a pipeline of small molecules against priority targets, enabling healthcare industry to focus on emerging fields of innate immunity, synthetic lethality and RNA modulation.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2019
- Employees
- 25
- Website
- 8five8tx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
858 Therapeutics’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.